Birgit C. Schultes - 01 Oct 2025 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: EVP, Chief Scientific Officer
Signature: James Basta, attorney-in-fact
Issuer symbol: NTLA
Transactions as of: 01 Oct 2025
Net transactions value: -$539
Form type: 4
Filing time: 03 Oct 2025, 17:13:56 UTC
Previous filing: 04 Mar 2025
Next filing: 07 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Schultes Birgit C	EVP, Chief Scientific Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE	James Basta, attorney-in-fact	03 Oct 2025	0002051419

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Sale	$539	-31	-0.03%	$17.38	105,184	01 Oct 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2025, and does not represent a volitional trade by the Reporting Person.

Remarks:

Exhibit 24.1 - Power of Attorney